Welcome to our dedicated page for Appian news (Ticker: APPN), a resource for investors and traders seeking the latest updates and insights on Appian stock.
Appian Corporation reports developments in process automation technology for large enterprises and governments. Its updates center on the Appian Platform, cloud subscription revenue, financial results, and business outlook, along with product enhancements that add AI-assisted spec-driven development, agentic automation, and Model Context Protocol integration.
Company news also covers customer and partner activity across enterprise and public-sector use cases, investor presentations and conference participation, and governance changes such as board appointments. The recurring themes link Appian’s subscription-based platform model with services, support, and automation capabilities for complex business operations.
On March 17, 2021, Appian (NASDAQ: APPN) announced that HP Hood LLC is utilizing its Workforce Safety solution to safely reintegrate 3,387 employees across 15 sites.
This solution includes Vaccination Insights, aiding employers in tracking vaccination status and COVID-19 history. The Workforce Safety solution can be deployed within hours on a secure cloud platform, ensuring comprehensive data management.
Key features include contact tracing, FDA-authorized testing, and incident management, making it vital for safe workplace operations.
Appian (NASDAQ: APPN) has been recognized as a 2021 Gartner Peer Insights Customers' Choice for Enterprise Low-Code Application Platforms. It is the only vendor to achieve this status in categories for Global Enterprises, Large Enterprises, North America, and the Finance industry. By December 31, 2020, Appian secured 109 reviews with an impressive overall rating of 4.7 out of 5. The company also announced new features in its Low-code Automation Platform, set to launch in March 2021, including low-code RPA, enhanced data unification, and intelligent document processing.
Appian (Nasdaq: APPN) reported financial results for Q4 and full year 2020, highlighting a 40% year-over-year increase in cloud subscription revenue to $36.9 million. For the full year, cloud subscription revenue rose 36% to $129.2 million, surpassing guidance. Total revenue for Q4 reached $81.6 million, up 19% from the previous year. Operating losses decreased, with GAAP net loss of $(6.4) million in Q4. For 2021, the company expects cloud subscription revenue between $167.5 million and $169.5 million, indicating 30-31% growth.
Appian (NASDAQ: APPN) announces that the University of Texas at Dallas is implementing the Appian Low-code Automation Platform for a new course on Intelligent Automation in the 2021/2022 academic year. This course will provide students practical skills in automation technologies including Robotic Process Automation and Intelligent Document Processing, culminating in certification as an Appian Level 1 Developer. UTD aims to prepare students for high-demand careers in automation, enhancing industry partnerships and workforce readiness.
On February 2, 2021, Appian (NASDAQ: APPN) announced the appointment of Denise Vu Broady as its new Chief Marketing Officer. Broady, with over 24 years of experience, previously led a $10 billion software business unit at SAP and will oversee Appian's marketing efforts. Her role aims to enhance the company's brand and drive growth in the low-code automation sector. Broady expressed excitement about Appian's potential and is set to accelerate its momentum globally. The press release highlights the increasing trend towards low-code platforms, with predictions indicating 75% of app development will use such technologies by the end of 2021.
Appian (NASDAQ: APPN) will release its fourth quarter and full year 2020 financial results on February 18, 2021, after market close. A conference call to discuss these results and the company's business outlook will be held at 5:00 p.m. ET. Investors can access the call via the Investor Relations page. The management team will also present at several upcoming investor conferences in late February and March 2021, including the KeyBanc Capital Markets and Morgan Stanley conferences.
Appian (NASDAQ: APPN) has joined Accenture's INTIENT partner ecosystem as a core partner aimed at enhancing integration between independent software vendors (ISVs) and life science companies. The partnership focuses on improving drug discovery and patient outcomes through the Accenture INTIENT Platform, which facilitates collaboration and efficiency in the life sciences sector. Appian's low-code development capabilities will allow organizations to build applications significantly faster, thereby supporting nine of the world's top ten drug and biotech firms.
On January 5, 2021, Appian Corporation (NASDAQ: APPN) announced its participation in two investor conferences. The company will present at the Needham Growth Conference on January 11 at 1:15 p.m. ET and at the Goldman Sachs Technology and Internet Conference on January 12 at 3:40 p.m. ET. Both presentations will be available via live webcast, with replays accessible under the “News & Events” section of Appian's investor relations website. Appian is known for its low-code automation platform that enhances business application development.
Appian (NASDAQ: APPN) has been recognized as a 2020 Tech100 Honoree by the Northern Virginia Technology Council, highlighting its impact in the Greater Washington technology sector. This prestigious list includes 100 tech companies and 26 executives, chosen by independent judges. CEO Matt Calkins expressed pride in the team's resilience during challenging times and their commitment to customer support. During the pandemic, Appian launched various applications, including a free Workforce Readiness app, aiding organizations worldwide, such as Garmin and Volkswagen, in ensuring safety amidst COVID-19.
Appian (NASDAQ: APPN) has joined Accenture's INTIENT partner ecosystem to enhance collaboration between independent software vendors and life sciences companies. This partnership aims to expedite drug discovery and improve patient outcomes. Appian's low-code automation platform allows for applications to be built up to 20x faster than traditional methods, benefiting productivity and innovation in drug development. The platform will integrate across various INTIENT product suites to deliver improved digital capabilities for life sciences clients.